Pulmonx (LUNG) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Pulmonx (NASDAQ:LUNG) reported third-quarter financial results on Tuesday. The transcript from the company's third-quarter earnings call has been provided below.This transcript is brought to you by Benzinga APIs. Forread more...
Pulmonx (LUNG) delivered earnings and revenue surprises of +26.92% and +3.75%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
Gainers
Neumora Therapeutics (NASDAQ:NMRA) shares rose 11.9% to $0.41 during Tuesday's after-market session. The market value of their outstanding shares is at $73.8 million.
Pulmonx (NASDAQ:LUNG) stock increasedread more...